(0.29%) 5 106.25 points
(0.70%) 38 652 points
(0.56%) 17 749 points
(0.05%) $78.99
(0.10%) $2.04
(-0.02%) $2 309.10
(-0.20%) $26.78
(1.48%) $976.80
(-0.16%) $0.931
(-0.60%) $10.93
(-0.23%) $0.796
(0.46%) $91.54
Live Chart Being Loaded With Signals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...
Stats | |
---|---|
今日成交量 | 78 085.00 |
平均成交量 | 132 475 |
市值 | 74.97M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $-0.450 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.0470 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-26 | List Alan | Buy | 868 | Common Stock |
2024-04-30 | List Alan | Sell | 238 | Common Stock |
2024-04-26 | List Alan | Sell | 868 | Restricted Stock Units |
2024-04-18 | Smith J. Jefferson | Buy | 31 343 | Restricted Stock Units |
2024-04-18 | Amoroso Michael | Buy | 111 217 | Restricted Stock Units |
INSIDER POWER |
---|
35.20 |
Last 99 transactions |
Buy: 6 086 461 | Sell: 2 083 491 |
音量 相关性
Precision BioSciences Inc 相关性 - 货币/商品
Precision BioSciences Inc 财务报表
Annual | 2023 |
营收: | $48.73M |
毛利润: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2023 |
营收: | $48.73M |
毛利润: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2022 |
营收: | $25.10M |
毛利润: | $16.09M (64.12 %) |
EPS: | $-41.95 |
FY | 2021 |
营收: | $115.53M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。